ABHD6 and multiple sclerosis: After the promising resultsof this first evaluation, the use of ABHD6 inhibitors was reassessedin multiple sclerosis by testing compounds 24 and 26, showing different CNS permeability.103 The administration of systemically active inhibitor 24 modestly attenuated the neurological disability of theEAE; on the contrary, the peripherally active inhibitor 26 was not effective in ameliorating the clinical signs of EAE.